BRINZOLAMIDE

Post-LOE

brinzolamide

Teva

ANDAOPHTHALMICSUSPENSION/DROPS

Approved

Nov 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

BRINZOLAMIDE (brinzolamide) by Teva is body, including the eye. Approved for elevated intraocular pressure (iop) in patients with ocular hypertension, open-angle glaucoma, the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension and 2 more indications. First approved in 2020.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

body, including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II, found primarily in red blood cells (RBCs), but…

Indications (5)

elevated intraocular pressure (IOP) in patients with ocular hypertension

Worked on BRINZOLAMIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT03896633Phase 1/2Completed

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Started Feb 2018

637 enrolled

GlaucomaOpen Angle or Ocular Hypertension

NCT03150160Phase 4Completed

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Started Sep 2017

1 enrolled

Glaucoma

NCT02339584Phase 3Completed

Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Started Apr 2015

493 enrolled

Open-Angle GlaucomaOcular Hypertension

NCT02140060Phase 2Completed

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Started Jun 2014

327 enrolled

GlaucomaOcular Hypertension

NCT01514734Phase 4Terminated

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Started Mar 2012

9 enrolled

Glaucoma